A+ R A-

Therapeutics in WM: Update on Monoclonal Antibody Trials

Please select from the following list of abstracts, representing the presentations given in Paris 2004 (IWWM-3) Session 9:

CHOP Plus Rituximab (CHOP-R) in Waldenstrom's Macroglobulinemia. Zachary Hunter, Andrew Branagan and Steven P. Treon.

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Steven P Treon, Zachary Hunter, Daniel Ditzel Santos, and Andrew Branagan.

CD52 Anitgen Expression in Waldenstrom's Macroglobulinemia and activity of Alemtuzumab in Patients With Relapsed/Refractory Disease. RG Owen, AC Rawstron, A Osterborg, J Lundin, G Svensson, P Hillmen.

CD52 Is Expressed On Human Mast Cells And Is A Therapeutic Target For The Anti-CD52 Monoclonal Antibody Campath-1H In Waldenstrom's Macroglobulinemia And Mast Cell Disorders. Daniel Ditzel Santos, Evdoxia Hatjiarissi, Olivier Tournilhac, Lian Xu, Andrew Branagan, Zachary Hunter, Mayan Catsells, Kenneth C Anderson and Steven P Treon.

Campath 1-H in Waldenstrom's Macroglobulinemia. Daniel Ditzel Santos, Zachary R Hunter, Andrew R Branagan and Steven P Treon.